{"id":55299,"date":"2026-01-23T15:10:42","date_gmt":"2026-01-23T07:10:42","guid":{"rendered":"https:\/\/flcube.com\/?p=55299"},"modified":"2026-01-23T15:10:43","modified_gmt":"2026-01-23T07:10:43","slug":"daiichi-sankyo-secures-breakthrough-therapy-designation-for-cdh6-targeted-adc-raludotatug-deruxtecan-in-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55299","title":{"rendered":"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer"},"content":{"rendered":"\n<p><strong>Daiichi Sankyo<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO:\u202f4568<\/a>) announced that <strong>Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a)<\/strong>, a first\u2011in\u2011class <strong>CDH6\u2011targeted antibody\u2011drug conjugate (ADC)<\/strong>, has received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from the U.S. <strong>FDA<\/strong> for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-clinical-context\">Regulatory Milestone &amp; Clinical Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Daiichi Sankyo (TYO:\u202f4568)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (FDA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Platinum\u2011resistant ovarian, peritoneal, or fallopian tube cancer (CDH6\u2011positive)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Post\u2011bevacizumab, advanced stage<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CDH6\u2011targeted ADC (anti\u2011CDH6 IgG1, peptide linker, topoisomerase I inhibitor)<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>No approved CDH6\u2011targeted therapies currently exist<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class:<\/strong> R\u2011DXd is the only ADC specifically targeting <strong>CDH6 (Cadherin\u20116)<\/strong>, a cell adhesion protein overexpressed in <strong>65\u201385% of ovarian cancers<\/strong><\/li>\n\n\n\n<li><strong>ADC Technology:<\/strong> Humanized anti\u2011CDH6 IgG1 monoclonal antibody, enzymatically cleavable peptide linker, and potent topoisomerase I inhibitor payload<\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> CDH6 overexpression correlates with <strong>poor prognosis<\/strong>, creating high unmet need in platinum\u2011resistant disease<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Novel target allows for precise tumor cell killing while sparing healthy tissue<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-with-merck\">Partnership Structure with Merck<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Collaboration:<\/strong> Daiichi Sankyo and <strong>Merck &amp; Co. (MSD outside US\/Canada)<\/strong> entered worldwide partnership in <strong>October\u202f2023<\/strong> for three ADCs: <strong>Patritumab deruxtecan, Ifinatamab deruxtecan, and Raludotatug deruxtecan<\/strong><\/li>\n\n\n\n<li><strong>Regional Rights:<\/strong> Daiichi Sankyo holds <strong>exclusive rights in Japan<\/strong>; Merck leads ex\u2011Japan development\/commercialization<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Daiichi Sankyo fully responsible for ADC manufacturing and supply<\/li>\n\n\n\n<li><strong>Expanded Agreement:<\/strong> In <strong>August\u202f2024<\/strong>, collaboration added <strong>MK\u20116070<\/strong> (bispecific), with Merck holding Japan rights and manufacturing responsibility<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ovarian Cancer Market:<\/strong> Global market valued at <strong>$2.5\u202fbillion<\/strong> in 2025; platinum\u2011resistant segment represents <strong>30%<\/strong> of patients with limited treatment options<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>$3\u20135\u202fbillion<\/strong> peak sales potential for R\u2011DXd in ovarian cancer if approved, based on CDH6 prevalence and lack of competition<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> BTD accelerates FDA review timeline, potential for <strong>2027 NDA submission<\/strong> and <strong>2028 launch<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Leverage:<\/strong> Validates Daiichi Sankyo\u2019s ADC platform, strengthening position in ADC leadership rivalry with AstraZeneca\/Daiichi\u2019s Enhertu franchise<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fII trial readout expected <strong>mid\u20112026<\/strong>; BTD enables rolling review and priority FDA engagement<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for Raludotatug Deruxtecan. Actual results may differ due to clinical trial outcomes, competitive developments, and FDA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,194,978],"class_list":["post-55299","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-daiichi-sankyo","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC), has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55299\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC), has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55299\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-23T07:10:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T07:10:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55299#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55299\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer\",\"datePublished\":\"2026-01-23T07:10:42+00:00\",\"dateModified\":\"2026-01-23T07:10:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55299\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Daiichi Sankyo\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55299#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55299\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55299\",\"name\":\"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-23T07:10:42+00:00\",\"dateModified\":\"2026-01-23T07:10:43+00:00\",\"description\":\"Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC), has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55299#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55299\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55299#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC), has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55299","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer","og_description":"Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC), has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.","og_url":"https:\/\/flcube.com\/?p=55299","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-23T07:10:42+00:00","article_modified_time":"2026-01-23T07:10:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55299#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55299"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer","datePublished":"2026-01-23T07:10:42+00:00","dateModified":"2026-01-23T07:10:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55299"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Daiichi Sankyo","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55299#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55299","url":"https:\/\/flcube.com\/?p=55299","name":"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-23T07:10:42+00:00","dateModified":"2026-01-23T07:10:43+00:00","description":"Daiichi Sankyo (TYO:\u202f4568) announced that Raludotatug Deruxtecan (R\u2011DXd, DS\u20116000a), a first\u2011in\u2011class CDH6\u2011targeted antibody\u2011drug conjugate (ADC), has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for adult patients with platinum\u2011resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer expressing CDH6 who have received prior bevacizumab therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55299#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55299"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55299#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6\u2011Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55299"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55299\/revisions"}],"predecessor-version":[{"id":55300,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55299\/revisions\/55300"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}